İLERİ EVRE/REKÜREN OVER KANSERİ NEDENİYLE HİPERTERMİK İNTRAPERİTONYAL KEMOTERAPİ (HIPEC) UYGULADIĞIMIZ HASTALARDAKİ PEROPERATİF TECRÜBEMİZ

Amaç: İleri evre/reküren over kanseri nedeniyle sitoredükti cerrahi ve Hipertermik İntraperitonyal Kemoterapi (HIPEC) uyguladımız hastalardaki peroperati morbidite ve mortaliteyi araştıdık. Yöntem: Ocak 2016-Aralık 2018 tarihleri arasında HIPEC uyguladığımız hastaların elektronik dosyaları ve takipleri retrospekti olarak incelendi. Bulgular: Nihai patolojisi musinöz apandiks tümörü gelen 1 vaka dışlandığında peritonyal karsinomatozis nedeniyle toplam 18 hastaya ileri cerrahi ve HIPEC uygulandı. Hastaların ortalama yaşı 54,6 (aralık, 22-76 yaş) idi. Median preoperati CA125 değeri 64 U/ml (aralık, 6-4756 U/ml) idi. 3 hasta rekürens nedeniyle, 15 hasta (11 interval, 4 fist-look cerrahi) ise primer olarak opere edildi. Hastaların hepsine peritonektomi prosedürü, 4 hastaya ise beraberinde barsak rezeksiyonu uygulandı. Ortalama operasyon süresi 323,5 dakika (aralık, 180- 495 dakika) idi. En sık gözlenen dahili morbidite, kan transfüzyonu (83.3%, 15/18); cerrahi morbidite ise yara yeri enfeksiyonu (%16.6, 3/18) bulundu. Hastaların ortalama hastanede yatı süresi 10,3 gün (aralık, 5-32 gün) idi. Peroperati mortalite gözlenmedi. Sonuç: HIPEC, yoğun bakım koşulları iyi olan ve multiisipliner kliniklerde uygulandiğında peroperati ciddi morbidite ve mortaliteye neden olmayan bir yöntemdir.

Our Peroperatie Experience in Patints who Underwent Hyperthermic Intraperitoneal Chemotherapy (Hipec) For Advanced Stage/Recurrent Ovarian Cancer

Objectie: We investiated peroperatie morbidity and mortality in patints who underwent cytoreductiesurgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced stage/recurrent ovariancancer.Methods: Between January 2016 and December 2018, electronic fies and follow-up of patints whounderwent HIPEC were reviewed retrospectiely.Results: Aftr one case of mucinous appendiceal tumor was excluded, a total of 18 patints underwentadvanced surgery and HIPEC due to peritoneal carcinomatosis were detected. The mean age of the patintswas 54.6 years (range, 22-76 years). The median preoperatie CA125 value was 64 U/ml (range 6-4756 U/ml). Fiften patints (11 interval surgeries, 4 fist-look surgeries) were operated primarily while 3 patintswere operated due to recurrent disease. Peritonectomy procedure was performed in all patints and bowelresectin was performed in 4 patints. The mean operatie tie was 323.5 minutes (range, 180-495 minutes).The most common medical morbidity was blood transfusion (83.3%, 15/18) while most common surgicalmorbidity was wound infectin (16.6%, 3/18). The mean length of hospitalizatin was 10.3 days (range, 5-32days). No peroperatie mortality was observed.Conclusion: HIPEC is a method that does not cause severe morbidity and mortality when well intensive careconditins are applied in multiisciplinary clinics

PDF

___

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statitis, 2011: the impact of eliminatig socioeconomic and racial disparitis on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.
2. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognosti factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138–50.
3. Chua TC, Moran B, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early and long-term outcome data on 2298 patints with pseudomyxoma peritonei of appendiceal origin treated by a strategy of cytoreductie surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449–56.
4. Yan TD, Deraco M, Barat i, Kusamura S, Elias D, Glehen O,et al. Cytoreductie surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multiinstiutinal experience. J Clin Oncol 2009;27:6237–42.
5. Elias D, Gilly F, Boutii F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperatie intraperitoneal chemotherapy:retrospectie analysis of 523 patints from a multientric French study. J Clin Oncol 2010;28:63–8.
6. Spilioti J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E., et al. Cytoreductie surgery and HIPEC in recurrent epithelial ovarian cancer: a prospectie randomized phase III study. Ann Surg Oncol. 2015 May;22(5):1570-5.
7. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240.
8. Chiva LM, Gonzalez-Marti A. A critial appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015 Jan;136(1):130-5.
9. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patints with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359–74.
10. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplati compared with paclitaxel and cisplati in patints with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
11. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplati and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.
12. Hotouras A, Desai D, Bhan C, Murphy J, Lampe B, Sugarbaker PH. Heated IntraPEritoneal Chemotherapy (HIPEC) for Patints With Recurrent Ovarian Cancer: A Systemati Literature Review. Int J Gynecol Cancer. 2016 May;26(4):661-70.
13. Chiva LM, Gonzalez-Marti A. A critial appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015 Jan;136(1):130-5.
14. Deraco M, Virzı` S, Iusco DR, Puccio F, Macrì A, Famulari C, et al. Secondary cytoreductie surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multinstiutinal study. BJOG. 2012;119:800Y809.
15. Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductie surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)for advanced ovarian carcinoma:a French multientre retrospectie cohort study of 566 patints. Eur J Surg Oncol. 2013 Dec;39(12):1435-43.